BioSyent Inc. (RX) EPS Estimated At $0.07 on May, 24

May 16, 2018 - By Susanne Funderburg

On May, 24 WallStreet awaited BioSyent Inc. (CVE:RX)’s earnings report, according to Faxor. Analysts have expectation on stock’s EPS of $0.07. That’s up 16.67 % from last year’s $0.06 EPS. V_RX’s profit could hit $1.01 million with 36.11 P/E in case $0.07 EPS is published. -30.00 % negative EPS growth is what Wall Street’s sees after $0.10 reported EPS previous quarter. The stock increased 0.60% or $0.06 during the last trading session, hitting $10.11.Currently BioSyent Inc. is after 0.00% change in last May 17, 2017. RX has 264 shares volume. RX underperformed by 11.55% the S&P 500.

BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally.The firm is valued at $146.55 million. The Company’s products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of papillary non-muscle invasive bladder cancer.28.08 is the P/E ratio. The company's products also comprise Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; and endoscopies, proctoscopies, rectoscopies, and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.